Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 4 | 2019 | 171 | 1.600 |
Why?
|
| Thrombolytic Therapy | 2 | 2019 | 182 | 0.610 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 125 | 0.580 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 165 | 0.570 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 47 | 0.560 |
Why?
|
| Physicians | 1 | 2022 | 442 | 0.550 |
Why?
|
| Heart Arrest | 1 | 2019 | 161 | 0.530 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 131 | 0.510 |
Why?
|
| Heart Ventricles | 2 | 2019 | 251 | 0.510 |
Why?
|
| Azathioprine | 1 | 2010 | 23 | 0.340 |
Why?
|
| Gastrointestinal Agents | 1 | 2010 | 30 | 0.330 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 56 | 0.330 |
Why?
|
| Intensive Care Units | 3 | 2022 | 454 | 0.310 |
Why?
|
| Crohn Disease | 1 | 2010 | 113 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 304 | 0.290 |
Why?
|
| Acute Disease | 3 | 2019 | 661 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 854 | 0.240 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 90 | 0.200 |
Why?
|
| Vascular Resistance | 2 | 2019 | 44 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.190 |
Why?
|
| Hemodynamics | 2 | 2019 | 236 | 0.180 |
Why?
|
| Echocardiography | 3 | 2019 | 460 | 0.170 |
Why?
|
| Prostaglandins I | 1 | 2020 | 2 | 0.170 |
Why?
|
| Acetamides | 1 | 2020 | 13 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 157 | 0.170 |
Why?
|
| Arterial Pressure | 1 | 2020 | 21 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2020 | 42 | 0.170 |
Why?
|
| Pyrazines | 1 | 2020 | 32 | 0.170 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2019 | 3 | 0.160 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2019 | 13 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 155 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 61 | 0.160 |
Why?
|
| Survival Rate | 2 | 2021 | 793 | 0.150 |
Why?
|
| Middle Aged | 7 | 2021 | 16545 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 295 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 172 | 0.150 |
Why?
|
| Humans | 12 | 2022 | 60133 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 78 | 0.150 |
Why?
|
| Registries | 1 | 2021 | 811 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2019 | 6136 | 0.150 |
Why?
|
| Adult | 5 | 2021 | 15982 | 0.140 |
Why?
|
| Male | 8 | 2021 | 27969 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2017 | 14 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 272 | 0.140 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 27 | 0.140 |
Why?
|
| Inpatients | 1 | 2019 | 300 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 2361 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 264 | 0.120 |
Why?
|
| Female | 8 | 2021 | 31235 | 0.120 |
Why?
|
| Lung | 1 | 2019 | 842 | 0.110 |
Why?
|
| Aged | 6 | 2021 | 13585 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1564 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2017 | 1934 | 0.080 |
Why?
|
| Infliximab | 1 | 2010 | 55 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 115 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 97 | 0.080 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 254 | 0.070 |
Why?
|
| Nitrofurantoin | 1 | 2006 | 10 | 0.070 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2006 | 4 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 16 | 0.070 |
Why?
|
| United States | 1 | 2016 | 7609 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 3131 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2021 | 4 | 0.050 |
Why?
|
| International Agencies | 1 | 2021 | 7 | 0.050 |
Why?
|
| Receptors, Epoprostenol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2020 | 18 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 39 | 0.040 |
Why?
|
| Iloprost | 1 | 2019 | 3 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 20 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2019 | 13 | 0.040 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2019 | 19 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5264 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 255 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 377 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 143 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 94 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 531 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 341 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 558 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 417 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 1591 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1214 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3621 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 1304 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5194 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4395 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 5958 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 910 | 0.010 |
Why?
|